United Therapeutics Acquired Thymmune Therapeutics For $140M In Cash
United Therapeutics Corporation (Nasdaq: UTHR ) announced today it has acquired Thymmune Therapeutics, Inc. ( Thymmune ), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies,